ALKOHOLBEHANDLING - Statens Institut for Folkesundhed

244
Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology
(Berl) 2004; 172(1):16-24.
245
Maler JM, Esselmann H, Wiltfang J, Kunz N, Lewczuk P, Reulbach U et al. Memantine inhibits ethanol-induced NMDA
receptor up-regulation in rat hippocampal neurons. Brain Res 2005; 1052(2):156-162.
246
Zakharova E, Malyshkin A, Kashkin V, Neznanova O, Sukhotina I, Danysz W et al. The NMDA receptor channel blocker
memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats. Behav Pharmacol
2004; 15(4):273-278.
247
Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol
dependence. Pharmacopsychiatry 2004; 37(1):37-40.
248
Raguraman J, Priyadharshini RK, Chandrasekaran R. Effects of topiramate in alcohol dependence. Aust NZJPsychiatry
2005; 39(8):736-737.
249
Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K et al. Oral topiramate for treatment of
alcohol dependence: a randomised controlled trial. Lancet 2003; 361(9370):1677-1685.
250
Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the
quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 2004; 61(9):905-912.
251
Rubio G, Ponce G, Jiménez-Arriero MA, Rodriguez R, Oliva JM, Ortiz S et al. Comparison between gabapentine and
acamprosate in the treatment of alcohol dependence patients. Eur Neuropsychopharmacol 2002; 12 Suppl 3:S398.
252
Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients
with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62(1):37-45.
253
Colombo G, Serra S, Brunetti G, Atzori G, Pani M, VaccaGetal.The GABA(B) receptor agonists baclofen and CGP 44532
prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol 2002; 37(5):499-503.
254
Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L et al. Baclofen efficacy in reducing alcohol craving
and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37(5):504-508.
255
Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of
alcoholism: a controlled study. Alcohol Clin Exp Res 1998; 22(3):573-579.
256
Johnson BA, O’Malley SS, Ciraulo DA, Roache JD, Chambers RA, Sarid-Segal O et al. Dose-ranging kinetics and behavioral
pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol
2003; 23(3):281-293.
257
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol
Clin Exp Res 2003; 27(7):1107-1122.
258
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot
feasibility study. Alcohol Clin Exp Res 2003; 27(7):1123-1131.
259
Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed
alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24(5):737-742.
260
Ait-Daoud N, Johnson BA, Javors M, Roache JD, Zanca NA. Combining ondansetron and naltrexone treats biological
alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker. Alcohol Clin
Exp Res 2001; 25(6):847-849.
Alkoholbehandling – en medicinsk teknologivurdering 119